Condition (MeSH)
Shock, Traumatic
ClinicalTrials.gov lists 18 trials for Shock, Traumatic or a narrower condition beneath it. Sangart has the most among industry and government lead sponsors, with 2.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
17 of the 18 trials are tagged with Shock, Traumatic itself; the rest are tagged with a narrower condition beneath it.
When did Shock, Traumatic trials start? (13)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 2
- Phase 3
- Not applicable
- Observational
Top of scale: 3
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2025 | 1 |
| 2023 | 1 |
| 2022 | 2 |
| 2019 | 2 |
| 2018 | 1 |
| 2016 | 1 |
| 2013 | 3 |
| 2011 | 1 |
| 2009 | 1 |
Showing 10 of 13 earlier years.
No forecast is made for this condition: it averages 0.8 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 18 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Shock, Traumatic trials in? (5)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 4 |
| Phase 3 | 1 |
| Not applicable | 5 |
| Observational | 7 |
How many Shock, Traumatic trials are recruiting? (5)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Recruiting | 1 |
| Completed | 11 |
| Terminated | 3 |
| Unknown status | 2 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Shock, Traumatic trials? (3)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Sangart | 2 |
| Arsenal Medical, Inc. | 1 |
| Neptunus Pharmaceuticals Inc. | 1 |
Which drugs are being tested for Shock, Traumatic? (2)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| PMI-150 (intranasal ketamine) | 1 |
| Norepinephrine | 1 |
Interventions as named in the registry (8)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| MP4OX | 2 |
| Vasopressins | 2 |
| Inj Etomidate | 1 |
| 4 factor Prothrombin Complex Concentrates | 1 |
| Observational | 1 |
Showing 5 of 8 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Shock, Traumatic trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| ARDS | 65 | 1 |
| Increased intracranial hemorrrhage | 41 | 1 |
| Hypernatremia that did not required therapeutic intervention | 14 | 1 |
| Hypernatremia that required therapeutic intervention | 12 | 1 |
| Acute Renal Failure | 10 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Shock, Traumatic? (34)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Endothelial glycocalyx shedding in patients with burns. | Burns : journal of the International Society for Burn Injuries | 2020 | Yes |
| Poor microcirculatory flow dynamics are associated with endothelial cell damage and glycocalyx shedding after traumatic hemorrhagic shock. | The journal of trauma and acute care surgery | 2018 | Yes |
| Gender differences in trauma, shock and sepsis. | Military Medical Research | 2018 | Yes |
| Comparison of compensatory reserve and arterial lactate as markers of shock and resuscitation. | The journal of trauma and acute care surgery | 2017 | Yes |
| Combat: Initial Experience with a Randomized Clinical Trial of Plasma-Based Resuscitation in the Field for Traumatic Hemorrhagic Shock. | Shock (Augusta, Ga.) | 2015 | Yes |
Showing 5 of 34 publications.
Sub-conditions in MeSH (1)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence and rare-disease identity.